Incorporating best practices and artificial intelligence into workflows improves success rates
Two factors largely drive the discontinuation of a drug development program, contributing to the low success rate for clinical trials: poor efficacy in humans and adverse events. Although a variety of factors contribute to adverse outcomes for a given therapy, there is also a growing appreciation for the nuanced role of genetics in determining the extent of an adverse outcome for a given individual. Findings related to this role as well as the inherent properties of the drug itself can be used to improve the overall success rates of a drug development program. In this report, we discuss how each step in the drug discovery phase is crucial to improving success rates and some of the best practices that could be incorporated into the workflow. Download the report now, then contact us to learn how Cortellis can help you improve your toxicology processes.